Wakabayashi Yasushi, Wada Hiroshi, Sakakura Kenichi, Yamamoto Kei, Mitsuhashi Takeshi, Ako Junya, Momomura Shin-ichi
Department of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Department of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
J Cardiol. 2015 Oct;66(4):341-6. doi: 10.1016/j.jjcc.2014.12.008. Epub 2015 Jan 19.
The optimal preoperative therapeutic strategy for patients with coronary artery disease (CAD) is an important concern in the era of drug-eluting stents and antiplatelet therapy. However, there are few studies about the impact of prior percutaneous coronary intervention (PCI) on perioperative major adverse cardiac events (MACEs) and bleeding events associated with oral antiplatelet therapy. The aim of this study was to examine the risks and benefits of performing PCI before non-cardiac surgery (NCS) in patients with CAD.
We investigated 130 patients who had angiographically significant and stable CAD and underwent NCS after index coronary angiography. We divided the patients into two groups: patients undergoing PCI with coronary stenting (PCI group), and those not undergoing PCI before NCS (no-PCI group), and compared the MACEs and bleeding events within 30 days from NCS between the groups.
There were 53 and 77 patients in the PCI and no-PCI groups, respectively. MACEs were observed in 2 patients (3.8%) in the PCI group and 3 patients (3.9%) in the no-PCI group (p=0.97), whereas bleeding events were observed in 10 (18.9%) and 8 patients (10.4%) in the PCI and no-PCI groups, respectively (p=0.17). There were no significant differences between the two groups in terms of MACEs and bleeding events.
The rate of MACEs following NCS was not significantly different between the PCI and no-PCI groups, while the rate of bleeding events was higher in the PCI group without reaching statistical significance. This study suggests that patients with stable CAD may be able to safely undergo NCS without revascularization even in the presence of significant coronary artery stenosis.
在药物洗脱支架和抗血小板治疗时代,冠心病(CAD)患者的最佳术前治疗策略是一个重要问题。然而,关于既往经皮冠状动脉介入治疗(PCI)对围手术期主要不良心脏事件(MACE)以及与口服抗血小板治疗相关的出血事件的影响的研究较少。本研究的目的是探讨CAD患者在非心脏手术(NCS)前进行PCI的风险和益处。
我们调查了130例经血管造影证实患有严重且稳定CAD并在首次冠状动脉造影后接受NCS的患者。我们将患者分为两组:接受冠状动脉支架置入PCI的患者(PCI组)和在NCS前未接受PCI的患者(非PCI组),并比较两组在NCS后30天内的MACE和出血事件。
PCI组和非PCI组分别有53例和77例患者。PCI组有2例患者(3.8%)发生MACE,非PCI组有3例患者(3.9%)发生MACE(p = 0.97),而PCI组和非PCI组分别有10例(18.9%)和8例患者(10.4%)发生出血事件(p = 0.17)。两组在MACE和出血事件方面无显著差异。
PCI组和非PCI组NCS后MACE发生率无显著差异,而PCI组出血事件发生率较高,但未达到统计学意义。本研究表明,即使存在严重冠状动脉狭窄,稳定CAD患者在不进行血运重建的情况下也可能能够安全地接受NCS。